Sarcoidosis is characterized by granulomatous inflammation developing in the affected organs. The ethiopathogenesis of the disease is still unknown. The lungs are most commonly affected, and uncontrolled, long-lasting inflammation can result in pulmonary fibrosis. Many different mediators, such as cytokines, chemokines, and other proteins with various functions that participate in its complex pathogenesis have been studied as markers of the disease. This article is a review of the available literature on the different markers. Although a considerable number of markers are elevated in the active stage of the disease, the studies conducted so far have shown that the values of serum ACE, IL-2R and chitotriosidase decrease with a good treatment response. KL-6 can be useful as a predictive marker for the development of pulmonary fibrosis in sarcoidosis. In conclusion, prospective studies with a larger number of patients will offer a much better insight considering the importance of these parameters when dealing with sarcoidosis.
Sharma OP, Vita JB. Determination of angiotensin-con verting enzyme activity in tears. A noninvasive test for evaluation of ocular sarcoidosis. Arch Ophthalmol. 1983;101(4):559–61.
2.
Johansen JS, N M, M H, C G, PA P, N G. Increased serum YKL-40 in patients with pulmonary sarcoidosis-a potential marker of disease activity? Respir Med. 2005;99(4):396 402.
3.
J K, S K. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sar coidosis. Chest. 1996;109(5):1276–82.
4.
Boot RG, Hollak CE, Verhoek M, Alberts C, Jonkers RE, Aerts JM. Plasma chitotriosidase and CCL18 as surro gate markers for granulomatous macrophages in sar coidosis. Clin Chim Acta. 2010;411(1–2):31–6.
5.
Brunner J, Scholl-Burgi S, Zimmerhackl LB. Chitotrio sidase as a marker of disease activity in sarcoidosis. Rheumatol Int. 2007;27:1171–2.
6.
Bargagli E, Maggiorelli C, Rottoli P. Human chitotriosi dase: a potential new marker of sarcoidosis severity. Respiration. 2008;76(2):234–8.
7.
Selroos O, Klockars M. Relation between clinical stage of sarcoidosis and serum values of angiotensin conveting enzyme and beta2-microglobulin. 1987;4(1):13–7.
8.
Eklund A, Blaschke E. Elevated serum neopterin levels in sarcoidosis. Lung. 1986;164(6):325–32.
9.
Grutters JC, Fellrath JM, Mulder L. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest. 2003;124:186–95.
10.
Rothkrantz-Kos S, Dieijen-Visser MP, Mulder PG. Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoido sis. Clin Chem. 2003;49:1510–7.
11.
Ziegenhagen MW, Rothe ME, Schlaak M, Muller Quernheim J. Bronchoalveolar and serological parame ters reflecting the severity of sarcoidosis. Eur Respir J. 2003;21(3):407–13.
12.
Perillie PE, Finch SC. Lysozyme in leukemia. Med Clin North Am. 1973;57(2):395–407.
Miyoshi S, Hamada H, Kadowaki T, Hamaguchi N, Ito R, Irifune K, et al. Comparative Evaluation of Serum Markers in Pulmonary Sarcoidosis. Chest. 2010;137:1391–7.
15.
Tahmoush AJ, Amir MS, Connor WW, Farry JK, Didato S, Ulhoa-Cintra A, et al. CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19(3):191–7.
16.
Hunninghake GW, Costabel U, AndoM. Ameri can Thoracic Society/European Respiratory Society/ World Association of Sarcoidosis and Other Granulo matous Disorders:statement onsarcoidosis. Sarc Vasc Dif Lung Dis. 1999;16:149–73.
17.
Gronhagen-Riska C, Selroos O, Niemisto M. Angioten sin converting enzyme. V. Serum levels as monitors of disease activity in corticosteroid-treated sarcoidosis. Eur J Respir Dis. 1980;61(2):113–22.
18.
Baughman RP, FernandezM B, CH M, J H, P. Comparison of gallium-67 scanning, bron choalveolar lavage, and serum angiotensin-converting enzyme levels in pulmonary sarcoidosis. Predicting res ponse to therapy. Am Rev Respir Dis. 1984;129:676 81.
19.
DeRemee RA, Rohrbach MS. Serum angiotensin-con verting enzyme activity in evaluating the clinical course of sarcoidosis.Ann InternMed. 1980;92(3):361–5.
20.
Tomita H, Ina Y, Sugiura Y, Sato S, Kawaguchi H, M M, et al. Polymorphism in the angiotensin-con verting enzyme (ACE) gene and sarcoidosis. Am J Res pir Crit Care Med. 1997;156(1):255–9.
21.
Bosi A, Borsotti M, Ghelli P, Tozzi P, Bellesi G, Rossi FP. Serum angiotensin-I-converting enzyme and lyso zyme levels in untreated and unsplenectomized pati ents with Hodgkin’s disease. Acta Haematol. 1984;71(5):329–33.
22.
Loddenkemper R, Kloppenborg A, Schoenfeld N, Grosser H, Costabel U. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis-result of a cooperative study in former West Germany and Switzerland. WATL Study Group Wissenschaftliche Ar beitsgemeinschaft fur die Therapie von Lungenkrank heitan Sarcoidosis Vasc Diffuse Lung Dis. 1998;15(2):178–82.
23.
Grutters JC, Drent M, Bosch JM. Sarcoidosis. Eur Res pir Mon. 2009;46:126–54.
24.
Iannuzzi MC, Rybicki BA, Med TASSNEJ. 2007;357:2153–65.
25.
Payan DG. Neuropeptides and inflammation: the role of substance P. Annu Rev Med. 1989;40:341–52.
26.
Weinstock JV, Blum AM, Kassab JT. Angiotensin II is chemotactic for a T-cell subset which can express mig ration inhibition factor activity in murine schistosomi asis mansoni. Cell Immunol. 1987;107(1):180–7.
27.
V MV, O S. Atlas of sarcoidosis- Pathogenesis, Diagnosis, and Clinical Features. Sprin ger. 2005;
28.
Filipović M, Djordjevic Z. Imunoloski aspekt sarkoidoze. Acta Fac Med Naiss. 2001;18:229–34.
29.
Pejčić T, Stanković I, Rančić M, Djordjević I, Lj I, Ristić L. Klinički i radiološki oblici sarkoidoze pluća. Ac ta Fac Med Naiss. 2004;21:23–6.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
